Solara Active Pharma Sciences Limited — Others, 26-07-2025: Copy of Newspaper Publication

Solara Active Pharma Sciences announced its Q1 results, reporting a total income from operations of Rs. 108.20 Cr and a net loss of Rs. 19.46 Cr. The board approved these consolidated financial results. Regarding the rights issue first call, the company received Rs. 149.49 Cr. Of this, Rs. 115.00 Cr was allocated to debt repayment and Rs. 23.27 Cr for general corporate purposes, as per the offer terms. In a strategic move, the company is exploring the demerger of its CRAMS and Polymers businesses into a separate listed entity, incorporating a new subsidiary, Synthix Global Pharma Solutions Limited. This initiative aims to unlock value for shareholders.